Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?

Pharmacotherapy provides an adjunct to behaviour modification in the management of obesity. There are a number of new drug therapies purportedly targeting appetite; liraglutide, and bupropion/naltrexone, which are European Medicines Agency and US Food and Drug Administration (FDA) approved, and lorc...

Descripción completa

Detalles Bibliográficos
Autores principales: Roberts, Carl A., Christiansen, Paul, Halford, Jason C. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504125/
https://www.ncbi.nlm.nih.gov/pubmed/28421338
http://dx.doi.org/10.1007/s00592-017-0994-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504125/
https://www.ncbi.nlm.nih.gov/pubmed/28421338
http://dx.doi.org/10.1007/s00592-017-0994-x

Ejemplares similares